Merck Aktie
WKN DE: A0YD8Q / ISIN: US58933Y1055
|
19.04.2024 13:42:02
|
Health Canada Approves Merck's Keytruda Plus Chemotherapy To Treat Gastric Cancers
(RTTNews) - Merck & Co Inc. (MRK) on Friday said its Keytruda in combination with fluoropyrimidine- and platinum-containing-chemotherapy has been approved by Health Canada for the treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults.
This approval is based on results from the Phase 3 KEYNOTE-859 trial, in which treatment with Keytruda plus chemotherapy showed statistically significant improvement in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to placebo in combination with chemotherapy in patients with gastric cancers.
Keytruda was first approved in 2014 by the US FDA to treat advanced or unresectable melanoma. It is currently approved for several indications including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, cervical cancer, among others.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
|
20:04 |
Montagshandel in New York: So bewegt sich der Dow Jones am Montagnachmittag (finanzen.at) | |
|
18:02 |
Starker Wochentag in New York: Dow Jones am Mittag fester (finanzen.at) | |
|
16:02 |
Dow Jones-Handel aktuell: Dow Jones-Anleger greifen zum Handelsstart zu (finanzen.at) | |
|
21.11.25 |
Gewinne in New York: Dow Jones beendet die Freitagssitzung in der Gewinnzone (finanzen.at) | |
|
21.11.25 |
Freundlicher Handel: Anleger lassen Dow Jones am Freitagnachmittag steigen (finanzen.at) | |
|
21.11.25 |
Gewinne in New York: So entwickelt sich der Dow Jones am Mittag (finanzen.at) | |
|
21.11.25 |
Freundlicher Handel: Dow Jones verbucht zum Handelsstart Zuschläge (finanzen.at) | |
|
20.11.25 |
Schwacher Handel in New York: Dow Jones verbucht Verluste (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
| Merck Co. | 88,00 | 2,33% |
|